Ciclopirox Olamine not checked

Atlas Molecular Pharma · ATL-001

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Congenital Erythropoietic Porphyria (CEP)
Main trialPhase 1/2
“This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD”In the company’s words, NCT07024316 on ClinicalTrials.gov
Other names
ATL-001

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 1 May 2028 A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
Phase 1Completed 8 Apr 2024 Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ciclopirox Olamine

Following is part of Solo: you see every change to Ciclopirox Olamine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in